Line Uhrenholt - Aalborg University Hospital

基本信息

浏览量：5

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 32 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Exploring TNFi Drug-Levels and Anti-Drug Antibodies During Tapering among Patients with Inflammatory Arthritis: Secondary Analyses from the Randomised BIODOPT Trial

Line Uhrenholt, Mads E. R. Sørensen, Karen B. Lauridsen,Kirsten Duch,Lene Dreyer,Robin Christensen,Ellen-Margrethe Hauge, Anne Gitte Loft, Mads N. B. Rasch,Hans Christian Horn,Peter C. Taylor,Kaspar R. Nielsen,Salome Kristensen

Rheumatology Internationalpp.1-12, (2024)

引用0浏览0WOS引用

POS0248 EXPLORING TUMOUR NECROSIS FACTOR INHIBITOR DRUG LEVELS DURING DISEASE ACTIVITY-GUIDED TAPERING IN PATIENTS WITH INFLAMMATORY ARTHRITIS: SECONDARY ANALYSES FROM THE BIODOPT TRIAL

M. Sorensen,S. Kristensen,K. B. Lauridsen,K. Duch,L. Dreyer,R. Christensen,E. M. Hauge,A. G. Loft,M. Nyhuus Bendix Rasch,H. C. Horn,P. C. Taylor,K. R. Nielsen,L. Uhrenholt

ANNALS OF THE RHEUMATIC DISEASES (2023): 359-360

引用0浏览0引用

Predicting Successful Biologics Tapering in Patients with Inflammatory Arthritis: Secondary Analyses Based on the BIOlogical Dose OPTimisation (BIODOPT) Trial

L. Uhrenholt,K. Duch,R. Christensen,L. Dreyer,E. M. Hauge,A. Schlemmer,P. C. Taylor,S. Kristensen

British Journal of Clinical Pharmacology（2023）

引用2浏览0WOS引用

POS0254 PREDICTING SUCCESSFUL TAPERING OF BIOLOGICS IN PATIENTS WITH INFLAMMATORY ARTHRITIS: SECONDARY ANALYSES FROM THE BIODOPT TRIAL

L. Uhrenholt,K. Duch,R. Christensen,L. Dreyer,E.M. Hauge,A. Schlemmer,P.C. Taylor,S. Kristensen

Annals of the Rheumatic Diseases (2023): 364

引用0浏览0引用

Certolizumab Pegol, Abatacept, Tocilizumab or Active Conventional Treatment in Early Rheumatoid Arthritis: 48-Week Clinical and Radiographic Results of the Investigator-Initiated Randomised Controlled NORD-STAR Trial

Annals of the rheumatic diseases（2023）

引用9浏览0WOS引用

Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial

ARTHRITIS & RHEUMATOLOGY (2023): 2606-2609

引用0浏览0引用

Disease Activity-Guided Tapering of Biologics in Patients with Inflammatory Arthritis: a Pragmatic, Randomized, Open-Label, Equivalence Trial

L. Uhrenholt,R. Christensen,L. Dreyer,E-M Hauge,A. Schlemmer,A. G. Loft,M. N. B. Rasch,H. C. Horn, K. H. Gade,R. D. Ostgard,P. C. Taylor,K. Duch,S. Kristensen

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY（2023）

引用8浏览0WOS引用

Isolation in Patients with Inflammatory Rheumatic Diseases During COVID-19 Pandemic Compared to Healthy Individuals: a Questionnaire Survey

Eriksen, Tobias Eschricht,Dinesen, Wilfred K. H.,Uhrenholt, Line,Dreyer, Lene,Duch, Kirsten,Kristensen, Salome

Rheumatology International（2022）

引用5浏览0WOS引用

OP0058 CERTOLIZUMAB-PEGOL, ABATACEPT, TOCILIZUMAB OR ACTIVE CONVENTIONAL THERAPY IN EARLY RHEUMATOID ARTHRITIS: CLINICAL AND RADIOGRAPHIC 48-WEEKS RESULTS OF THE INVESTIGATOR-INITIATED RANDOMIZED NORD-STAR TRIAL

Annals of the Rheumatic Diseasesno. Suppl 1 (2022): 38.2-40

引用2浏览0引用

OP0022 DISEASE ACTIVITY-GUIDED TAPERING OF BIOLOGICS IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A RANDOMISED, OPEN-LABEL, EQUIVALENCE TRIAL

L. Uhrenholt,R. Christensen,L. Dreyer,E. M. Hauge,A. Schlemmer,A. G. Loft,M. Nyhuus Bendix Rasch,H. C. Horn, K. Gade,P. C. Taylor,S. Kristensen

Annals of the rheumatic diseases（2022）

引用2浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn